Likewise, in separate analyses for HER‐2 negative and positive tumours (Tables S5 and S6), odds ratios were not significantly different between them, but trends were highly significant for the former, which were the great majority, and mainly not significant for the latter, which were <10% of the total (Table S5). The gene discussed is ERBB2; the disease is neoplasm.